ENT-02

ENT-02 is an investigational small molecule drug candidate currently in preclinical development by Enterin for the treatment of Autistic Disorder. Developed as part of Enterin's focus on the enteric nervous system (ENS) and the gut-brain axis, ENT-02 is intended to address neurodevelopmental symptoms by modulating signaling pathways within the gastrointestinal tract. While the specific molecular target and chemical structure of ENT-02 have not been publicly disclosed, the company's therapeutic approach typically involves the use of aminosterols or other small molecules to influence neural function and proteostasis originating in the gut.